Bedrijfsoverzicht
Jazz Pharmaceuticals plc is a biotechnology company that identifies, develops, and commercializes pharmaceutical products across the United States, Europe, and international markets. The firm operates within the healthcare sector, specifically focusing on the biotechnology industry, which involves the discovery and production of medicines for specific therapeutic indications. The company employs 2,890 individuals and holds a market capitalization of $11.96B with a trailing twelve-month revenue of $4.27B. These valuation and revenue figures indicate that Jazz Pharmaceuticals has established itself as a significant player with substantial asset value relative to its current sales output, positioning it within the mid-to-large cap range of the pharmaceutical landscape.
Financiële gezondheid
The company reported a revenue of $4.27B for the trailing twelve months, yet posted a net income of $-356,148,000 while maintaining an EBITDA of $1.71B. The substantial gap between the positive EBITDA of $1.71B and the negative net income reveals a cost structure where significant non-operating expenses, such as interest payments or taxes, are eroding bottom-line profitability despite strong operational cash generation. Free cash flow stands at $1.35B, which indicates a robust capacity to fund operations, invest in research and development, or return capital without relying on external financing. Gross margins are reported at 91.7%, operating margins at 27.1%, and profit margins at -8.3%, highlighting a highly efficient production process but an overall inability to generate net profit from sales due to the aforementioned structural costs. Liquidity analysis shows the company holds $2.44B in cash against total debt of $5.43B, resulting in a debt-to-equity ratio of 125.67, which suggests a leveraged balance sheet where debt obligations exceed shareholder equity. The current ratio is 1.86, indicating that the company possesses sufficient current assets to cover its short-term liabilities with a comfortable margin of safety. Return on equity is -8.5% and return on assets is 5.4%, metrics that reveal management is currently generating positive returns on the total asset base but failing to generate returns specifically attributable to shareholders due to the net loss position.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is listed as N/A due to the negative net income, while the forward P/E ratio is 7.74, implying that the market prices in significant expected earnings growth to reach profitability. The price-to-book ratio is 2.76, suggesting that the market values the company at a premium of 2.76 times its book value, which often reflects the high intangible value of intellectual property and future pipeline potential rather than current book equity. Alternative valuation metrics show a price-to-sales ratio of 2.80 and an EV/EBITDA of 8.71, indicating that investors are willing to pay nearly three times annual sales for the company, a multiple consistent with biotech firms that have high growth expectations but current profitability challenges. The stock trades between a 52-week high of $200.24 and a 52-week low of $97.50, establishing a trading range that defines the recent volatility and investor sentiment thresholds for the security. The beta value is 0.23, which signifies that the stock price exhibits significantly lower volatility relative to the broader market, moving less than a quarter of the magnitude of market swings.
Growth & Income
Revenue growth year-over-year is 10.1%, while earnings growth year-over-year is 3.2%, indicating that earnings are currently growing at a slower pace than revenue, likely due to the high fixed costs and interest expenses affecting the bottom line. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm does not distribute cash to shareholders but instead retains all earnings to fund its R&D pipeline and operational expansion. The overall growth and income profile is characterized by double-digit top-line expansion supported by strong cash generation, while income growth remains constrained by structural cost factors and the absence of a dividend distribution policy.